ThromboGenics and BioInvent Announce Results from Phase IIb VTE Prevention Study with TB-402

News   Jul 05, 2012

 
ThromboGenics and BioInvent Announce Results from Phase IIb VTE Prevention Study with TB-402
 
 
 

RELATED ARTICLES

Arsenic Trioxide Could Extend Lives of Patients with Aggressive Brain Cancer

News

Arsenic trioxide could be a powerful therapy that could extend the lives of certain glioblastoma patients by as much as three to four times the median expectation.

READ MORE

XenoGesis and Juniper Pharma Services Strengthen Alliance

News

Campanies extend strategic alliance in early drug development services.

READ MORE

Quotient Clinical Signs Cocrystal Agreement with Nuformix

News

Partnership to evaluate cocrystal formulations using translational pharmaceutics.

READ MORE

 

Comments | 0 ADD COMMENT

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE